NovoCure Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
NovoCure has a total shareholder equity of $360.8M and total debt of $654.5M, which brings its debt-to-equity ratio to 181.4%. Its total assets and total liabilities are $1.2B and $861.2M respectively.
Anahtar bilgiler
181.4%
Borç/özkaynak oranı
US$654.48m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$959.90m |
| Eşitlik | US$360.78m |
| Toplam yükümlülükler | US$861.21m |
| Toplam varlıklar | US$1.22b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: N2VC34's short term assets ($1.1B) exceed its short term liabilities ($735.0M).
Uzun Vadeli Yükümlülükler: N2VC34's short term assets ($1.1B) exceed its long term liabilities ($126.2M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: N2VC34 has more cash than its total debt.
Borcun Azaltılması: N2VC34's debt to equity ratio has increased from 78.5% to 181.4% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: N2VC34 has sufficient cash runway for more than 3 years based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if N2VC34 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.